Exploring regulatory data sets of the Comirnaty vaccine - Second part
A summary of posts
In post 9 of the series, we explained our methods for identifying PK data.
and in the following posts, 9a to 9e
we explained that the PK data seen by regulators lacked numbers and details, for example, with a lack of genotoxicity and carcinogenicity studies. In post 9b, we reported our understanding of the production of the misreported mRNA (alias mmRNA)
…